Literature DB >> 22760531

Delayed versus immediate antimicrobial treatment for acute otitis media.

Paula A Tähtinen1, Miia K Laine, Olli Ruuskanen, Aino Ruohola.   

Abstract

BACKGROUND: Watchful waiting with the option of delayed antimicrobial treatment for acute otitis media is recommended in several guidelines. Our aim was to study whether delayed, as compared with immediate, initiation of antimicrobial treatment worsens the recovery from acute otitis media in young children.
METHODS: Children (6-35 months) with acute otitis media received either delayed or immediate antimicrobial treatment with amoxicillin-clavulanate for 7 days. The delayed antimicrobial treatment group (n = 53) consisted of placebo recipients from a randomized-controlled trial to whom antimicrobial treatment was initiated after a watchful waiting period. The immediate antimicrobial treatment group (n = 161) consisted of children allocated to receive antimicrobial treatment immediately.
RESULTS: Improvement during antimicrobial treatment (which includes both symptoms and otoscopic signs) was observed in 91% and 96% of children in the delayed and immediate antimicrobial treatment groups, respectively (P = 0.15). Median watchful waiting period was 48 hours. Delayed initiation of antimicrobial treatment was associated with prolonged resolution of fever, ear pain, poor appetite and decreased activity, but not ear rubbing, irritability, restless sleep or excessive crying. Parents of children in the delayed antimicrobial treatment group missed more work days (mean 2.1 versus 1.2 days, P = 0.03). Diarrhea, vomiting and rash were equally common in both groups.
CONCLUSIONS: Our results indicate that delayed initiation of antimicrobial treatment does not worsen the recovery from acute otitis media, as measured by improvement during treatment. However, watchful waiting before the initiation of delayed antimicrobial treatment might be associated with transient worsening of a child's condition, prolongation of symptoms and economic losses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22760531     DOI: 10.1097/INF.0b013e318266af2c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Streptococcus salivarius by nasal spray for recurrent otitis: how good is the evidence?

Authors:  S Di Mario; V Basevi; R D'Amico; C Gagliotti; M Gangemi; F Marchetti; M L Moro; G Tamburlini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-14       Impact factor: 3.267

2. 

Authors:  Teeranai Sakulchit; Ran D Goldman
Journal:  Can Fam Physician       Date:  2017-09       Impact factor: 3.275

3.  Parental acceptability of the watchful waiting approach in pediatric acute otitis media.

Authors:  Arnon Broides; Olga Bereza; Noga Lavi-Givon; Yariv Fruchtman; Eli Gazala; Eugene Leibovitz
Journal:  World J Clin Pediatr       Date:  2016-05-08

4.  Low Concentrations of Nitric Oxide Modulate Streptococcus pneumoniae Biofilm Metabolism and Antibiotic Tolerance.

Authors:  Raymond N Allan; Samantha Morgan; Sanjita Brito-Mutunayagam; Paul Skipp; Martin Feelisch; Stephen M Hayes; William Hellier; Stuart C Clarke; Paul Stoodley; Andrea Burgess; Hasnaa Ismail-Koch; Rami J Salib; Jeremy S Webb; Saul N Faust; Luanne Hall-Stoodley
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 5.  Antibiotics for acute otitis media in children.

Authors:  Roderick P Venekamp; Sharon L Sanders; Paul P Glasziou; Chris B Del Mar; Maroeska M Rovers
Journal:  Cochrane Database Syst Rev       Date:  2015-06-23

Review 6.  Antibiotic therapy for children with acute otitis media.

Authors:  Teeranai Sakulchit; Ran D Goldman
Journal:  Can Fam Physician       Date:  2017-09       Impact factor: 3.275

7.  Xylitol for the prevention of acute otitis media episodes in children aged 2-4 years: protocol for a pragmatic randomised controlled trial.

Authors:  Nav Persaud; Andreas Laupacis; Amir Azarpazhooh; Catherine Birken; Jeffrey S Hoch; Wanrudee Isaranuwatchai; Jonathan L Maguire; Muhammad M Mamdani; Kevin Thorpe; Christopher Allen; Dalah Mason; Christine Kowal; Farnaz Bazeghi; Patricia Parkin
Journal:  BMJ Open       Date:  2018-08-05       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.